SciClone Pharmaceuticals, Inc.  

(Public, NASDAQ:SCLN)   Watch this stock  
Find more results for SCLN
11.15
Oct 13 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 8.55 - 11.43
Open     -
Vol. 0.00
Mkt cap 581.94M
P/E 12.96
Div/yield     -
EPS 0.86
Shares 52.19M
Beta     -
Inst. own 76%

Key stats and ratios

Q2 (Jun '17) 2016
Net profit margin 27.39% 19.19%
Operating margin 27.67% 20.76%
EBITD margin - 21.37%
Return on average assets 18.42% 13.40%
Return on average equity 20.24% 15.56%
Employees 570 -
CDP Score - -

Address

950 Tower Ln Ste 900
FOSTER CITY, CA 94404-2125
United States - Map
+1-650-3583456 (Phone)
+1-650-3583469 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

SciClone Pharmaceuticals, Inc. is a pharmaceutical company. The Company's product portfolio of therapies includes oncology, infectious diseases and cardiovascular disorders. The Company's business is focused primarily in the People's Republic of China. The Company operates in two segments: China and the Rest of the World, including its operations in the United States and Hong Kong. The Company's lead product ZADAXIN (thymalfasin) is approved in over 30 countries, which is used for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV), and certain cancers according to the local regulatory approvals, and for use as an immune system enhancer. In addition to ZADAXIN, SciClone markets seven partnered and in-licensed products in China. The Company sells ZADAXIN in various international markets through its subsidiary, SciClone Pharmaceuticals International Ltd. (SPIL). Its development portfolio includes Angiomax, Loramyc, Neucardin, VIBATIV and Cleviprex.